Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q1 2025 Earnings Call Transcript
Operator: Hello and thank you for standing by. My name is Tiffany, and I will be your conference operator today.
Jazz Pharmaceuticals Plc (JAZZ)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Lee Munder Capital Group Lee Munder | 74,370 | $9,233,036 | +64% | 0.61% |
| 2. | Leucadia National Ian Cumming And Joseph Steinberg | 11,213 | $1,392,094 | 0.01% | |
| 3. | Bayforest Capital Theodoros Tsagaris | 1,795 | $142,648 | 0.12% | |
| 4. | Hurley Capital Charles Goldblum | 200 | $24,830 | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $119.65 | 12,000 | Officer | 27,932 | 2024-03-01 | Filing | |
| $112.32 | 11,482 | Director | 1,152,788 | 2020-05-27 | Filing | |
| $111.56 | 9,884 | Director | 1,141,306 | 2020-05-27 | Filing | |
| $110.52 | 8,391 | Director | 1,131,422 | 2020-05-27 | Filing | |
| $109.55 | 5,243 | Director | 1,123,031 | 2020-05-27 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $120.00 | 500 | Officer, Director | 438,807 | 2025-05-02 | Filing | |
| $116.35 | 1,000 | Officer, Director | 439,307 | 2025-05-01 | Filing | |
| $123.75 | 1,500 | Officer, Director | 440,307 | 2025-04-01 | Filing | |
| $138.41 | 2,403 | Officer | 79,621 | 2025-03-10 | Filing | |
| $137.81 | 1,140 | Officer | 7,012 | 2025-03-10 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,017,403 | $747,060,582 | 0.01% | |
| 2. | 5,765,331 | $715,765,783 | 0.02% | |
| 3. | 952,172 | $118,212,154 | 1.43% | |
| 4. | 844,705 | $104,870,126 | 0.25% | |
| 5. | 615,717 | $76,441,266 | 0.01% |
News See All
Billionaire Ray Dalio's Bridgewater's 10 Stock Picks with Huge Upside Potential
Up until February 18, 2025, the stock market seemed poised to replicate the 2020-2022 bull run. Save for slight corrections in April and August of 2024, the market was in a general upside trend.
10 Best Mid Cap Biotech Stocks to Buy
On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC's 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
12 Most Promising Biotech Stocks According to Wall Street Analysts
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.
10 Cash-Rich Mid Cap Stocks To Buy Now
Cash flow is the money moving in and out of a business over a set period. It is important because it shows how much cash a company actually has on hand, rather than just looking at profits on paper.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q4 2024 Earnings Call Transcript
Operator: Thank you for standing by. My name is Jeannie, and I will be your conference operator today.
14 Best 52-Week High Stocks To Buy According to Analysts
After two years of substantial gains to record highs, exhaustion in the US equity markets is slowly kicking in.
8 Most Undervalued Pot Stocks to Buy According to Analysts
A decade ago, the cannabis industry was in full swing as stock valuations exploded to record highs in states across the country legalizing pot use for medicinal and recreational purposes.
Silver Ring Value Partners: Jazz Pharmaceuticals (JAZZ) Is a “High Uncertainty With Low Risk” Investment
Silver Ring Value Partners, an investment management company, released its third-quarter 2024 investor letter. A copy of the letter can be downloaded here.
10 Best Immunotherapy Stocks to Buy Now
The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by 2033.